News >

FDA Approves Cemiplimab for CSCC

Jason M. Broderick @jasoncology
Published: Friday, Sep 28, 2018

The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

At a median follow-up of 7.9 months, 28 of 59 patients had a response, including 4 (6.8%) complete responses and 24 (40.7%) partial responses. Among the responders, 57% had responses >6 months, and 82% had an ongoing response and continued to receive the PD-1 inhibitor. Responses were observed irrespective of prior systemic therapy.

The phase II trial included patients with either metastatic or locally advanced CSCC. The data presented at ASCO were only for the cohort of 59 patients with metastatic disease. These patients received cemiplimab intravenously at 3 mg/kg every 2 weeks. The median age of the 59 patients was 71 (range, 38-93), with 43 (73%) patients aged ≥65 years. 

Ninety-two percent of patients were male, 39% had and ECOG performance score of 0 and 61% had a score of 1. The primary site of CSCC included head or neck (64%), arm or leg (20%), and trunk (15%). Forty-four percent of patients were treatment naive, 37% had 1 prior regimen for CSCC, and 19% had ≥2 prior regimens. Three-fourths (76%) of patients had distant metastasis and 24% had regional metastasis only. 

The median time to response was 1.9 months (range 1.7-6.0). The median duration of response had not been reached at the data cutoff.  Beyond the 47.4% (95% CI, 34-61) ORR, the stable disease rate was 15% (n = 9) and the progressive disease rate was 19% (n = 11). Twelve percent (n = 7) of patients could not be evaluated and 7% (n = 4) had nontarget lesions only. The durable disease control rate (DCR) was 61.0% (95% CI, 47.4-73.5). 

The ORR in treatment-naive patients was 57.7% (15/26; 95% CI, 36-9-76.6), including 3 complete responses and 12 partial responses. The durable DCR was 69.2% (95% CI, 48.2-85.7). Among previously treated patients, the ORR was 39.4% (13/33; 95% CI, 22.9-57.9), including 1 CR and 12 PRs. The durable DCR was 54.5% (95% CI, 36.4-71.9). 

Grade ≥3 adverse events (AEs) occurred in 42% of patients, leading to treatment discontinuation in 3 patients, and were linked to 3 patient deaths. Grade ≥3 AEs included diarrhea (n = 1), fatigue (n = 1), constipation (n = 1), anemia (n = 1), and pneumonitis (n = 2). Serious AEs occurred in 29% of patients. There were also 8 patient deaths due to disease progression. 

The article published in NEJM also included phase I study data from expansion cohorts of patients with locally advanced or metastatic CSCC. The findings were for 26 patients treated with the same cemiplimab dose as in the phase II study. The ORR was 50% (95% CI, 30-70) among these patients, comprising all partial responses (n = 13). Six patients had stable disease, 3 had progressive disease, 3 could not be evaluated, and 1 had nontarget lesions only. The durable DCR was 65% (95% CI, 44-83) and the median time to response was 2.3 months (95% CI, 1.7-7.3). 
 

References

  1. Rischin CD, Migden MR, Chang A, et al. Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). J Clin Oncol. 2018;36 (suppl; abstr 9519).
  2. Migden MR, Rischin CD, Schmults A, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma [published online June 4, 2018]. N Engl J Med. doi: 10.1056/NEJMoa1805131.

 



... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x